Empowered Patient Podcast

Dr. Jon Morrow, Senior VP of Medical Affairs and Informatics, and Daniel Blumenthal, Vice President of Strategy at MDClone, shed light on the meaning of synthetic data for drug discovery and patient care. Using both original data and statistical models of the data, researchers and clinicians can quickly gain insights that can impact patient care, facilitate collaborations and partnerships, and dramatically shorten the time required for product development.

Daniel explains, "Actually, the system is able to produce synthetic data on the fly on demand. It reacts to the end user's request for data. So, if I'm an end user and I want to build a population, I want to look at a population of patients with diabetes and understand the medications they were on and lab tests that were drawn about them. To understand their disease trajectory over time. I'm able to define that, and the way our engine works is it actually can take that original population. But without sharing that population, as John articulated at the beginning, without actually sharing that original population. Just learn the statistics of that population and then build this brand new set of synthetic data. That synthetic data, every time it's generated, is compared to the original."

Jon elaborates, "So rather than exposing my patient's information or using my patient's information with approval, how about if I ask a system like MDClone ADAMS to generate a synthetic dataset that looks statistically exactly like my population of patients with gestational diabetes? And it's pulling the data from the electronic medical record at my hospital. It's running this process behind the firewall of my hospital, but it's providing me with data on a population that doesn't exist but behaves exactly like my patients at the population level."

@MDClone_ #SyntheticData #LifeScience #ResearchData #RareDiseases

mdclone.com

Listen to the podcast here

Dr. Jon Morrow, Senior VP of Medical Affairs and Informatics, and Daniel Blumenthal, Vice President of Strategy at MDClone, shed light on the meaning of synthetic data for drug discovery and patient care. Using both original data and statistical models of the data, researchers and clinicians can quickly gain insights that can impact patient care, facilitate collaborations and partnerships, and dramatically shorten the time required for product development.

Daniel explains, "Actually, the system is able to produce synthetic data on the fly on demand. It reacts to the end user's request for data. So, if I'm an end user and I want to build a population, I want to look at a population of patients with diabetes and understand the medications they were on and lab tests that were drawn about them. To understand their disease trajectory over time. I'm able to define that, and the way our engine works is it actually can take that original population. But without sharing that population, as John articulated at the beginning, without actually sharing that original population. Just learn the statistics of that population and then build this brand new set of synthetic data. That synthetic data, every time it's generated, is compared to the original."

Jon elaborates, "So rather than exposing my patient's information or using my patient's information with approval, how about if I ask a system like MDClone ADAMS to generate a synthetic dataset that looks statistically exactly like my population of patients with gestational diabetes? And it's pulling the data from the electronic medical record at my hospital. It's running this process behind the firewall of my hospital, but it's providing me with data on a population that doesn't exist but behaves exactly like my patients at the population level."

@MDClone_ #SyntheticData #LifeScience #ResearchData #RareDiseases

mdclone.com

Download the transcript here

Ardy Arianpour, CEO and Co-Founder of SEQSTER, is breaking down health data silos using their enterprise operating system, which aggregates disparate health data sources, including real-world data, into a single 360-degree view of a patient in real-time. This integrated approach with a Digital Front Door solves many challenges for life sciences, patient engagement, and data interoperability.

Ardy elaborates, "We have achieved nationwide coverage of electronic health records from hospitals and medical groups, as well as genomic DNA labs, wearables, remote patient monitoring sensors, pharmacy data, and even social determinants of health data. And we have this very unique customizable white label approach where SEQSTER provides accelerated access to de-identified tokenized real-time data and comprehensive curated data to address critical needs across the healthcare continuum."

"For about five years, nobody wanted to work with us. We were just building, building, building, being visionary, as we thought. Then the pandemic hit, and Takeda Pharmaceuticals decided to invest in SEQSTER and do a commercial deal with us. From there, we created the SEQSTER data backbone for Takeda to centralize all this health data. And since we pioneered a longitudinal health record and pharma was the first to take a look at our technology, from there, we are able to strike many partnerships. We just exploded in the last two and a half years, I could say."

@SEQSTER #PatientCentric #HealthDataIsMedicine #PatientEngagement #ClinicalTrials #DecentralizedTrials #Interoperability #OutcomesStudies #HEOR #RWD #RWE #SaaS. #SanDiego

SEQSTER.com

Medium Article: Participant Digital Front Door

Listen to the podcast here

Ardy Arianpour, CEO and Co-Founder of SEQSTER, is breaking down health data silos using their enterprise operating system, which aggregates disparate health data sources, including real-world data, into a single 360-degree view of a patient in real-time. This integrated approach with a Digital Front Door solves many challenges for life sciences, patient engagement, and data interoperability.

Ardy elaborates, "We have achieved nationwide coverage of electronic health records from hospitals and medical groups, as well as genomic DNA labs, wearables, remote patient monitoring sensors, pharmacy data, and even social determinants of health data. And we have this very unique customizable white label approach where SEQSTER provides accelerated access to de-identified tokenized real-time data and comprehensive curated data to address critical needs across the healthcare continuum."

"For about five years, nobody wanted to work with us. We were just building, building, building, being visionary, as we thought. Then the pandemic hit, and Takeda Pharmaceuticals decided to invest in SEQSTER and do a commercial deal with us. From there, we created the SEQSTER data backbone for Takeda to centralize all this health data. And since we pioneered a longitudinal health record and pharma was the first to take a look at our technology, from there, we are able to strike many partnerships. We just exploded in the last two and a half years, I could say."

@SEQSTER #PatientCentric #HealthDataIsMedicine #PatientEngagement #ClinicalTrials #DecentralizedTrials #Interoperability #OutcomesStudies #HEOR #RWD #RWE #SaaS. #SanDiego

SEQSTER.com

Medium Article: Participant Digital Front Door

Download the transcript here

Alex Nepogodiev is a Divisional Vice President of Abbott Vascular Business and shares insights about the need for stents with larger diameters. In the past, physicians would have to take a smaller diameter stent and follow up with another catheter to expand that stent to a larger size and to match the vessel. This procedure added an additional step and risk.

Alex explains, "Some of the bigger challenges today are, of course, the variation in anatomy and the complexity of some of those narrowings that we have in our heart. Cardiovascular disease, obviously, impacts a lot of patients, and myself included, and it's important for us not only to maintain good health but also go for appropriate and timely checkups. And when the cardiologist finds a narrowing in our heart, they initiate the procedure by first doing an x-ray or an angiogram before proceeding to insert a stent. And once they do that, they can also use other imaging modalities to look more closely at the vessel."

"So XIENCE Skypoint large vessel sizes have been introduced now with the largest size matrix and the new diameters that come in vessel sizes of 4.5 or 5.0 millimeters in diameter. And what they allow us to do is treat patients who may have larger vessels. We're all unique, and some of us are patients who are larger male or we have vessels that are closer to the aorta. So those tend to be larger in diameter as well. And having these larger vessel sizes allows the physicians to, again, optimize and personalize treatments to those particular situations in those patients."

@AbbottCardio #Stents #DrugElutingStents #InterventionalCardiologist #Cardiology #CardiovascularDisease

cardiovascular.abbott.com

Listen to the podcast here

Alex Nepogodiev is a Divisional Vice President of Abbott Vascular Business and shares insights about the need for stents with larger diameters. In the past, physicians would have to take a smaller diameter stent and follow up with another catheter to expand that stent to a larger size and to match the vessel. This procedure added an additional step and risk.

Alex explains, "Some of the bigger challenges today are, of course, the variation in anatomy and the complexity of some of those narrowings that we have in our heart. Cardiovascular disease, obviously, impacts a lot of patients, and myself included, and it's important for us not only to maintain good health but also go for appropriate and timely checkups. And when the cardiologist finds a narrowing in our heart, they initiate the procedure by first doing an x-ray or an angiogram before proceeding to insert a stent. And once they do that, they can also use other imaging modalities to look more closely at the vessel."

"So XIENCE Skypoint large vessel sizes have been introduced now with the largest size matrix and the new diameters that come in vessel sizes of 4.5 or 5.0 millimeters in diameter. And what they allow us to do is treat patients who may have larger vessels. We're all unique, and some of us are patients who are larger male or we have vessels that are closer to the aorta. So those tend to be larger in diameter as well. And having these larger vessel sizes allows the physicians to, again, optimize and personalize treatments to those particular situations in those patients."

@AbbottCardio #Stents #DrugElutingStents #InterventionalCardiologist #Cardiology #CardiovascularDisease

cardiovascular.abbott.com

Download the transcript here

Dr. Tom Milam is the Chief Medical Officer at Iris Telehealth, which focuses on providing in-person and digital support to community mental health centers, Federally Qualified Health Centers, and rural health clinics that don't have enough access to behavioral health providers. The populations they treat are often underserved and have social determinants of health that are barriers to accessing timely care.

Tom elaborates, "We're also working a lot in emergency rooms and hospitals around the country. Seeing patients there with behavioral health issues, again in organizations that don't have enough providers. And that seems to be par for the course around the country for a lot of hospitals and health systems. They need additional providers, and we're happy to provide those through telepsychiatry at Iris."

"The positive thing about telepsychiatry really is that it eliminates the geographic barriers that are huge barriers for people getting care. So we can get our excellent providers into areas that have a really hard time recruiting onsite providers. So other than that, one of the things I say is that telepsychiatry is a technology. That's all that it is."

@IrisHealth #IrisTelehealth #Telepsychiatry #Telepsychiatrist #Psychiatrist #BehavioralHealth #EmergencyDepartments #RuralHospitals #MedicaidPatients #MedicarePatients #SDoH

iristelehealth.com

Listen to the podcast here

Dr. Tom Milam is the Chief Medical Officer at Iris Telehealth, which focuses on providing in-person and digital support to community mental health centers, Federally Qualified Health Centers, and rural health clinics that don't have enough access to behavioral health providers. The populations they treat are often underserved and have social determinants of health that are barriers to accessing timely care.

Tom elaborates, "We're also working a lot in emergency rooms and hospitals around the country. Seeing patients there with behavioral health issues, again in organizations that don't have enough providers. And that seems to be par for the course around the country for a lot of hospitals and health systems. They need additional providers, and we're happy to provide those through telepsychiatry at Iris."

"The positive thing about telepsychiatry really is that it eliminates the geographic barriers that are huge barriers for people getting care. So we can get our excellent providers into areas that have a really hard time recruiting onsite providers. So other than that, one of the things I say is that telepsychiatry is a technology. That's all that it is."

@IrisHealth #IrisTelehealth #Telepsychiatry #Telepsychiatrist #Psychiatrist #BehavioralHealth #EmergencyDepartments #RuralHospitals #MedicaidPatients #MedicarePatients #SDoH

iristelehealth.com

Download the transcript here

Scott Gray is the President and CEO of Clincierge and is focused on streamlining clinical trial recruitment, retention, and completion and improving the results of trials to speed time to approval. Clincierge is most concerned about the challenges presented by travel needs and logistics for patients, caregivers, and family members.

Scott explains, "Our mission is to lead the global clinical trial performance improvement market. So a lot of my experience has been in leadership development with my pharma customers and performance improvement. And as we created Clincierge over the last seven years, we felt that what we could do in the space, being non-medical in our approach, that we could help with the patient experience and thereby influence the overall outcome to the improvement of clinical trials."

"We positioned it in the space of clinical trials and helping those who want to conduct clinical trials, especially sponsors, to better understand what patients are asking for or to better understand the challenges that patients face when they want to participate in a clinical trial. As an example, 62% of patients and 59% of the caregivers said that travel stopped them from participating in a clinical trial. And 42% of patients and 47% of caregivers said financial issues stop them from participating."

"Well, with patients having a better experience, there's a lot of building of trust. Because some other reasons that patients drop out are not only the financial and travel burdens, but they may feel underappreciated. They have work pressures, losing work, losing wages from not being at work."

@Clincierge #ClinicalTrials #ClinicalResearch #ClinicalTrialRecruitment #PatientExperience #RareDiseases #Pharma #Biotech

Clincierge.com

Listen to the podcast here

Scott Gray is the President and CEO of Clincierge and is focused on streamlining clinical trial recruitment, retention, and completion and improving the results of trials to speed time to approval. Clincierge is most concerned about the challenges presented by travel needs and logistics for patients, caregivers, and family members.

Scott explains, "Our mission is to lead the global clinical trial performance improvement market. So a lot of my experience has been in leadership development with my pharma customers and performance improvement. And as we created Clincierge over the last seven years, we felt that what we could do in the space, being non-medical in our approach, that we could help with the patient experience and thereby influence the overall outcome to the improvement of clinical trials."

"We positioned it in the space of clinical trials and helping those who want to conduct clinical trials, especially sponsors, to better understand what patients are asking for or to better understand the challenges that patients face when they want to participate in a clinical trial. As an example, 62% of patients and 59% of the caregivers said that travel stopped them from participating in a clinical trial. And 42% of patients and 47% of caregivers said financial issues stop them from participating."

"Well, with patients having a better experience, there's a lot of building of trust. Because some other reasons that patients drop out are not only the financial and travel burdens, but they may feel underappreciated. They have work pressures, losing work, losing wages from not being at work."

@Clincierge #ClinicalTrials #ClinicalResearch #ClinicalTrialRecruitment #PatientExperience #RareDiseases #Pharma #Biotech

Clincierge.com

Download the transcript here